A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine

Condition:   Respiratory Disorders Interventions:   Biological: NTHi Mcat investigational vaccine (GSK3277511A);   Biological: Placebo Sponsor:   GlaxoSmithKline Not yet recruiting

Source: ClinicalTrials.gov - February 23, 2018 Category: Research Source Type: clinical trials